Send us Fan Mail

Join us as we return to our discussion on the fascinating ADePT trial in Glioblastoma brain tumours with the wonderful Dr Faye Robertson from the Western General Hospital, Edinburgh.

We discuss how TGX-007 developed with TROGENIX with its super enhancers, dual payload and delivery system hopes to bring a break through in High grade Gliomas.

We talk about how could this technology be 'rolled out' if successful. What level of success would be needed to develop the specialism for this kind of treatment.

Could this therapy be adapted to be used in other cancer types such as pancreatic cancer etc ?

With only 1 human trial patient clearly this is early days but we hope to follow this trial's progress on The Simply Oncology Podcast.

Even if the survival outcomes of the trial were negative this trials move the dial in terms of what is possible from drug development and delivery.

Send us Fan Mail

Sometimes we hear about a vision for a trial that is so novel and exciting that it takes you back a bit.

This is one such moment.

Join us as we talk to the amazing Dr Faye Robertson from the Edinburgh cancer Centre about the ingenious ADePT trial.

DUAL PAYLOAD GENE THERAPY.

Led by Trogenix and the University of Edinburgh, it tests a breakthrough "Trojan horse" gene therapy designed to destroy cancer cells and stimulate the immune system.

TGX-007 is a drug developed with Tregonix that:

How it Works: It uses dual-payload technology to deliver two distinct therapeutic agents:

1. HSV-tk: Converts an orally administered antiviral drug (valaciclovir) into a toxic agent that directly kills proliferating tumour cells.
2. IL-12: Acts as an immune-stimulating cytokine that turns the tumour into an in-situ vaccine, training the body's immune system to attack the cancer and prevent recurrence.

We have had many false dawns in GBM trials but we are very excited by the results so far with TGX-007.

Part 1 of 2 and this is a trial story we want to follow through.

Enjoy!!!

Send us Fan Mail

We return to discuss the role of radiotherapy in the management of Pancreatic Cancer.

What are the side effects of pancreatic radiotherapy and SABR?

Do we need an MR Linac to deliver pancreatic SABR

Where might pancreatic RT sit alongside new RAS inhibitor therapies?

Enjoy

Send us Fan Mail

Today we are talking about the role of radiotherapy in Pancreatic Cancer with the superb Dr Ganesh Radhakrishna from the Christie Hospital in Manchester.

Radiotherapy may play an increasing role in pancreatic cancer. Stereotactic ablative body radiotherapy (SABR) is helping to get excellent control rates in localised pancreatic cancer and may play a role alongside surgery in pancreatic cancer.

Will radiotherapy ever replace surgery in select cases?

Send us Fan Mail

Join us as we talk to Annie Anderson to get a patient view on advanced kidney cancer and its treatment.

Annie was diagnosed with stage IV Kidney Cancer in 2022 which had spread to liver, bone, brain.

She went from climbing and running 18 miles to struggling to function.

She describes the choices she made and how immunotherapy with has controlled her cancer and allowed her to continue her normal life.

A really powerful thing to hear how Annie has tackled her diagnosis and aimed to take positive steps every day.

She describes how continuing the things that give her joy like family, cold-water swimming and climbing have allowed her retain her sense of self along the way.

You cannot help but be inspired.

Enjoy

Send us Fan Mail

Join us as we complete our tour of the adjuvant kidney cancer treatment space.

We are joined again by the excellent Dr Will Ince from Cambridge and Dr Naveen Vasudev from Leeds!

In our last episode we discussed KEYNOTE 564 and the RAMPART study and where this places immunotherapy in adjuvant kidney cancer.

In this episode we discuss the LITESPARK 022 trial and the addition of Belzutifan to Pembrolizumab in adjuvant kidney cancer treatment.

We also discuss the potential for KIM-1 to be used as a biomarker to highlight those higher risk patients that may benefit from adjuvant immunotherapy.

This is an exciting time for adjuvant treatment in kidney cancer.

All this as Will continues to misbehave to amuse himself!!

We hope you enjoy!

Send us Fan Mail

Joins us as we celebrate 100 episodes in style!!

In the first of our 2 part special we tackle the Adjuvant Treatment Landscape in Kidney Cancer.

We talk to Dr Will Ince from Addenbrookes Hospital Cambridge and Dr Naveen Vasudev from St James’s Hospital Leeds.

We discuss the arrival of immunotherapy with the KEYNOTE 564 trial.

We discuss the importance of the RAMPART study and backing up the concept of a survival signal from immunotherapy in adjuvant Kidney cancer.

We discuss our concept of risk and benefit.

Nav steers us through this evolving landscape whilst Will Ince generally misbehaves!!!

Enjoy

Send us Fan Mail

Welcome back for Part 2 of our Early Melanoma series with Dr Toby Talbot.

We dive in to the potential side effects of treatment and how this affects decisions about adjuvant treatment.

We hear about adjuvant BRAF targeted therapy, with more side effects but temporary ones.

We look at the future with the NADINA trial for neoadjuvant immunotherapy in high risk clinical stage III disease, the emerging role of cancer vaccines, and biomarkers to try and find the right treatment for the right patient.

Tour de force as always. Keep an eye out for upcoming podcasts on the treatment of advanced/metastatic melanoma.